<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="163034">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01787396</url>
  </required_header>
  <id_info>
    <org_study_id>LG-DPCL011</org_study_id>
    <nct_id>NCT01787396</nct_id>
  </id_info>
  <brief_title>Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d</brief_title>
  <official_title>A Multicenter, Randomized, Active-controlled, Parallel Group, Double-blind, Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d Compared With Either Monotherapy in Treatment naïve Patients With Type 2 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate efficacy and safety of initial combination
      therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in
      treatment naïve patients with type 2 diabetes, In other words, to proof superiority of
      initial combination therapy with Gemigliptin and Metformin than each monotherapy.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">May 2015</completion_date>
  <primary_completion_date type="Anticipated">November 2014</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>HbA1c</measure>
    <time_frame>24weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Evaluation variables at week 24 to baseline(Visit 2(randomization), week 0)</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">429</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg + Metformin Once daily with dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Gemigliptin 50mg + Placebo(Metformin)Once daily with dinner</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin+ Placebo(Gemigliptin 50mg)Once daily with dinner</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemigliptin 50mg</intervention_name>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(Metformin)</intervention_name>
    <arm_group_label>Arm 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <arm_group_label>Arm1</arm_group_label>
    <arm_group_label>Arm3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo(Gemigliptin)</intervention_name>
    <arm_group_label>Arm3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients with type 2 diabetes mellitus

          2. Adults over 20 of age

          3. Patients with hemoglobin A1c (HbA1c) over 7.5% at Visit1(screening) and no previous
             antidiabetic drugs before Visit 1(screening) or patients with hemoglobin A1c (HbA1c)
             between 7%~10.5%, Patients treated with metformin monotherapy before Visit
             1(screening).

             Patients with no previous antidiabetic drugs

          4. Patients with hemoglobin A1c (HbA1c) between 7.5%~11% at Visit 2(randomization)

        Exclusion Criteria:

          1. Patients with type 1 diabetes mellitus Diabetic ketoacidosis or Hyperosmolar
             non-ketotic coma.

          2. Patients with gestational diabetes, or secondary diabetes

          3. Patients with New York Heart Association (NYHA) class III-IV congestive heart failure
             or patients with arrhythmia requiring treatment

          4. Patients with dysfunctional thyroid gland (with abnormal level of TSH)

          5. Patients with active bladder cancer.

          6. Tests which need to be given radiation iodide dye by intravenous.(ex, intravenous
             urography, intravenous cholangiography, angiography, CT with dye)

          7. Severe infection, pre or post operation.(Simple surgery which does not have
             restriction of food and fluid), severe trauma patient.

          8. Patients with pituitary insufficiency or adrenal dysfunction.

          9. Patients with pulmonary infarction, severe pulmonary dysfunction, hypoxemia.

         10. Patients with gastrointestinal disorders(ex. Dehydration, Diarrhea, Vomiting)

         11. Female patients who is gravida or in lactiferous phase or confirmed pregnancy by
             serum or urine.

         12. Patients with body mass index (BMI) below 20 kg/m2 or exceeding 40 kg/m2

         13. Male patients with Serum Creatinine level over 1.5mg/dl, Female patients with serum
             creatinine over 1.4mg/dl.

         14. Patients with alanine aminotransferase (ALT), aspartate aminotransferase (AST),
             exceeding 2.5 times or bilirubin exceeding 1.5 times of the upper limit of the normal
             range

         15. Patients who were taking or needed to take any drugs that may affect the control of
             blood glucose significantly (ex. glucocorticoids)

         16. Patients taking thyroid hormone, warfarin, dicoumarin or digoxin.

         17. Patients taking CYP3A4 inducers.(ex, Rifampicin(Rifampin), Dexametha-sone, Phenytoin,
             Carbamazepine, Rifabutin, Phenobarbital)

         18. Patients taking Furocemide, Nifedipine, Cimetidine

         19. Patients who were treated with Anti-obesity drugs in the last 12 weeks prior to Visit
             1(screening)

         20. Patients who were treated with insulin or glucagon-like peptide-1 (GLP-1) analogue or
             in the last 6 months prior to Visit 1.

         21. Patients who had experienced myocardial infarction, unstable angina or prior history
             of coronary artery bypass surgery within 6 months prior to Visit1(screening), or
             patients with arrhythmia requiring treatment

         22. Patients with history of addiction to alcohol or drugs within 1year prior to Visit
             1(screening).

         23. Patients with history of Diabetic ketoacidosis or Hyperosmolar non-ketotic coma.

         24. Patients with history of hypersensitivity to gemiglpitin or
             Dipeptidyl-peptidase4(DPP4) inhibitors.

         25. Patients with history of hypersensitivity to metformin or biguanides.

         26. Patients with history of hypersensitivity to Pioglitazone HCl or Thiazolidinediones

         27. Patients who participated in other clinical trial within 3 months prior to
             Visit1(screening).

         28. Patients with other reasons who the investigator decided not to be eligible for the
             study
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ji Yung Ahn, BS</last_name>
    <phone>82-2-6924-3164</phone>
    <email>jiyungbori@lgls.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>LG Life Sciences</name>
      <address>
        <city>Seoul</city>
        <zip>110-062</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Yung Ahn, BS</last_name>
      <phone>82-2-6924-3164</phone>
      <email>jiyungbori@lgls.com</email>
    </contact>
    <investigator>
      <last_name>Jae Myung Yu, MD,PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 27, 2013</lastchanged_date>
  <firstreceived_date>February 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
